{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:53:37Z","timestamp":1786985617470,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.canrad.2017.07.038","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T22:01:19Z","timestamp":1504562479000},"page":"597-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Doses dans les organes \u00e0 risque en radioth\u00e9rapie conformationnelle et en radioth\u00e9rapie en conditions st\u00e9r\u00e9otaxiques\u00a0: la vessie"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-0637","authenticated-orcid":false,"given":"L.","family":"Duverg\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Liz\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2017.07.038_bib0300","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semradonc.2007.09.007","article-title":"Intensity-modulated radiation therapy: supportive data for prostate cancer","volume":"18","author":"Cahlon","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0305","first-page":"743","article-title":"Nomograms to predict late urinary toxicity after prostate cancer radiotherapy","volume":"32","author":"Mathieu","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0310","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ijrobp.2010.04.041","article-title":"Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix","volume":"80","author":"Hasselle","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0315","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijrobp.2013.06.2059","article-title":"Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study","volume":"87","author":"Gandhi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0320","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.radonc.2011.07.012","article-title":"Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer","volume":"100","author":"P\u00f6tter","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0325","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2006.11.005","article-title":"Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy","volume":"67","author":"Chen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0330","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jfma.2013.09.013","article-title":"Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy","volume":"113","author":"Chen","year":"2014","journal-title":"J Formos Med Assoc Taiwan Yi Zhi"},{"key":"10.1016\/j.canrad.2017.07.038_bib0335","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2016.07.004","article-title":"Simultaneous integrated boost volumetric modulated arc therapy in the postoperative treatment of high-risk to intermediate-risk endometrial cancer: results of ADA II phase 1-2 trial","volume":"96","author":"Macchia","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0340","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.prro.2016.06.005","article-title":"Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma","volume":"7","author":"He","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0345","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1748-717X-7-45","article-title":"IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center","volume":"7","author":"Vieillot","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0350","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.radonc.2009.07.006","article-title":"A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy","volume":"93","author":"Devisetty","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0355","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0360","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.canrad.2016.07.014","article-title":"Recommandations en radioth\u00e9rapie externe et curieth\u00e9rapie (Recorad)\u00a0: 2e \u00e9dition","volume":"20","author":"Mah\u00e9","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.07.038_bib0365","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.canrad.2016.07.037","article-title":"Radioth\u00e9rapie externe des cancers prostatiques","volume":"20","author":"de Crevoisier","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.07.038_bib0370","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.canrad.2016.07.011","article-title":"Radioth\u00e9rapie des cancers du col et de l\u2019endom\u00e8tre","volume":"20","author":"Barillot","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.07.038_bib0375","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/j.canrad.2016.07.061","article-title":"Radioth\u00e9rapie des cancers du canal anal","volume":"20","author":"Peiffert","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.07.038_bib0380","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.canrad.2016.07.043","article-title":"Radioth\u00e9rapie des cancers du rectum","volume":"20","author":"Peiffert","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.07.038_bib0385","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.canrad.2016.07.010","article-title":"Radioth\u00e9rapie des cancers de vessie","volume":"20","author":"Riou","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.07.038_bib0390","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.canrad.2016.07.032","article-title":"D\u00e9lin\u00e9ation des organes \u00e0 risque et contraintes dosim\u00e9triques","volume":"20","author":"No\u00ebl","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.07.038_bib0395","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0400","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0405","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0410","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0415","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0420","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13566-012-0067-2","article-title":"Stereotactic body radiation therapy for the primary treatment of localized prostate cancer","volume":"2","author":"Oliai","year":"2013","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0425","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0430","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2490-13-49","article-title":"A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy","volume":"13","author":"Bolzicco","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0435","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0360-3016(00)00700-8","article-title":"Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial","volume":"48","author":"Storey","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0440","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2005.06.002","article-title":"A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy","volume":"76","author":"Nichol","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0445","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2007.04.076","article-title":"Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose\u2013volume analysis of a phase II dose-escalation study","volume":"69","author":"Harsolia","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0450","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2009.01.062","article-title":"Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I\/II dose escalation study","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0455","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70Gy versus 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0460","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2014.01.015","article-title":"Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial","volume":"88","author":"Hoffman","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0465","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","article-title":"A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer","volume":"78","author":"Arcangeli","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0470","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.clon.2008.08.006","article-title":"Phase I\/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3","volume":"20","author":"Tang","year":"2008","journal-title":"Clin Oncol R Coll Radiol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0475","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0480","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1748-717X-8-171","article-title":"Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study","volume":"8","author":"Alongi","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0485","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0490","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00432-014-1732-1","article-title":"Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life","volume":"140","author":"Scorsetti","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0495","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-6-3","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes","volume":"6","author":"Freeman","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0500","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2017.07.038_bib0505","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13566-015-0237-0","article-title":"Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer","volume":"5","author":"Oliai","year":"2016","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0510","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fonc.2016.00184","article-title":"The comparison of stereotactic body radiation therapy and intensity-modulated radiation therapy for prostate cancer by NCCN Risk Groups","volume":"6","author":"Ricco","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0515","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2006.01.062","article-title":"Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy","volume":"102","author":"Beriwal","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0520","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ijrobp.2007.10.021","article-title":"Assessment of extended-field radiotherapy for stage IIIC endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy","volume":"70","author":"Lian","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0525","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/02841860903410372","article-title":"Dosimetric comparison of postoperative whole pelvic radiotherapy for endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy","volume":"49","author":"Yang","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0530","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2014.01.018","article-title":"Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial","volume":"111","author":"Barillot","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0535","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1748-717X-2-41","article-title":"Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans","volume":"2","author":"Menkarios","year":"2007","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0540","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clon.2011.09.014","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network","volume":"24","author":"DeFoe","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2017.07.038_bib0545","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2011.07.030","article-title":"Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial","volume":"102","author":"Li","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0550","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.ijrobp.2011.01.051","article-title":"Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer","volume":"82","author":"Samuelian","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0555","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2013.10.026","article-title":"Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome","volume":"110","author":"Engels","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0560","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1748-717X-9-70","article-title":"Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II\/III rectal adenocarcinoma: results of a phase II study","volume":"9","author":"Zhu","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0565","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0360-3016(98)00037-6","article-title":"Estimation of the incidence of late bladder and rectum complications after high-dose (70-78Gy) conformal radiotherapy for prostate cancer, using dose\u2013volume histograms","volume":"41","author":"Boersma","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0570","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(98)05180-0","article-title":"Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial","volume":"353","author":"Dearnaley","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2017.07.038_bib0575","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0360-3016(98)00406-4","article-title":"Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study","volume":"43","author":"Koper","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0580","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0360-3016(00)01428-0","article-title":"Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose\u2013volume analysis","volume":"49","author":"Teh","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.07.038_bib0585","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0167-8140(02)00185-8","article-title":"Dose\u2013volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer","volume":"64","author":"Nuyttens","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.07.038_bib0295","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2009.08.004","article-title":"Dose\u2013volume effects for normal tissues in external radiotherapy: pelvis","volume":"93","author":"Fiorino","year":"2009","journal-title":"Radiother Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321817303347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321817303347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:28:18Z","timestamp":1761136098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321817303347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":59,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1278321817303347"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2017.07.038","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doses dans les organes \u00e0 risque en radioth\u00e9rapie conformationnelle et en radioth\u00e9rapie en conditions st\u00e9r\u00e9otaxiques\u00a0: la vessie","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2017.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}